Evidence map›Paper›PMID 35200692›Full record

ArticleJournal of cardiovascular development and disease2022

A Case of T/NK-Cell Post-Transplantation Lymphoproliferative Disease 7 Years after Heart Transplantation.

Makiko Nakamura, Teruhiko Imamura, Kohji Takagi, Masakazu Hori, Shinichi Tanaka, Joji Imura, Koichiro Kinugawa

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cardiovascular development and disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 58% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Makiko NakamuraThe Second Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan.ORCID 0000-0002-9604-5603
Teruhiko ImamuraThe Second Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan.ORCID 0000-0002-7294-7637
Kohji TakagiDepartment of Diagnostic Pathology, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan.ORCID 0000-0001-5095-6420
Masakazu HoriThe Second Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan.
Shinichi TanakaDepartment of Diagnostic Pathology, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan.
Joji ImuraDepartment of Diagnostic Pathology, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan.
Koichiro KinugawaThe Second Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan.
University of Toyama · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Post-transplant lymphoproliferative diseases (PTLD) are potentially fatal complications after cardiac transplantation. Most cases are Epstein-Barr virus (EBV)-related B-cell tumors, and reduction of immunosuppression treatment as well as the use of rituximab in combination with other chemotherapy are effective. However, patients with T/NK-cell PTLD post-cardiac transplantation are rarely reported. We had a patient with a fever that lasted for three weeks, with lung infiltrations and hepatosplenomegaly, who had EBV-associated hemophagocytosis 7 years after heart transplantation and was eventually diagnosed with T/NK-cell PTLD by autopsy. Although rare diseases, regular monitoring of EBV-DNA levels might be crucial for early diagnosis and treatment of PTLD.

Indexed as

cardiomyopathyEpstein–Barr virushemophagocytosisimmunosupressant

Identifiers

PMID35200692
PMCPMC8878054
OpenAlexW4210748355

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.